While the AI boom has disrupted funding patterns across the startup sphere, biotech has remained a rare steady sector for investment. For the past few years, global funding to biotech startups has hovered between $36 billion and $40 billion, and per Crunchbase data, 2026 is on track to stay close to that range. That stability matters because overall venture investment rose to a record level in the first half of this year, yet much of that largesse went to a couple of generative AI behemoths. Against that backdrop, biotechs still scooped up a respectable share of what was left, suggesting the sector has not been crowded out by the AI capital rush.
The mechanics of this year's funding show a mix of steady baseline activity and concentrated AI-adjacent deals. So far this year, more than $6 billion has gone to AI-focused biotechs, per Crunchbase data. The largest round—and the biggest for any biotech this year—was a $2.1 billion Series B for London-based Isomorphic Labs, which describes itself as an AI-first drug design and development company. Delaware-based Earendil Labs, which develops AI platforms for protein therapeutics, was the second-largest fundraiser, closing on $787 million in March. San Francisco's Chai Discovery, a startup applying AI to drug discovery, secured $400 million in a Series C this summer at a $3.8 billion valuation. Not all heavily funded biotechs are AI-centric, however: NewLimit, a longevity startup focused on restoring youthful function in old cells, raised $435 million in a June Series C.
The evidence comes from a single Crunchbase News analysis published on August 31, 2026, which draws on Crunchbase funding and exit data. The source notes that funding rounds this year are heavily tilted toward seed and early stage, which comprise more than half of all investment and most rounds. That pattern is consistent with prior years, as later-stage biotechs often seek to go public after a Series B or Series C financing rather than raise another venture round. The dossier does not include corroborating data from other providers, so the $36 billion to $40 billion range and the $6 billion AI-biotech figure should be read as Crunchbase's own tallies rather than independently verified market statistics.
The sector implications are twofold. First, biotech is holding up as a stable destination for venture capital even as AI dominates headlines and mega-rounds. Second, the exit environment remains active: at least 12 funded companies sold in transactions valued at $1 billion or more, including potential milestone payments, and several young biotechs went public. Kailera Therapeutics, a developer of obesity therapies founded in 2024, went public in April, six months after closing its Series B. Personalized medicine startup Kardigan made its Nasdaq debut in June after raising more than $550 million in early-stage funding the prior year, and Latigo Biotherapeutics completed its IPO in August, about a year-and-a-half after its Series B. The year's largest biotech offering came from 10-year-old Parabilis Medicines, which raised its Series F in January.
Still, the picture is not especially bullish. The source cautions that conditions look tame compared to the exuberance of the AI investment blitz. A key limitation is that the dossier contains only one source read in full, so the analysis cannot compare Crunchbase's figures with other data providers or confirm whether the steady range reflects resilient demand or simply a lack of breakout growth. What to watch is whether funding at the intersection of AI and biotech continues to accumulate and whether that enthusiasm spills over into the broader biotech sector in coming quarters.